Objectives: To investigate the clinical, pathological, and survival characteristics of locoregional breast cancer patients receiving neoadjuvant chemotherapy (NACT). Methods: Breast cancer patients at Cumhuriyet University Oncology Center between January 2010 and December 2022 were evaluated retrospectively. Results: The study included 177 patients. After NACT, 43 (24%) of the patients achieved pCR. Pre-NACT clinicopatholog ical data, including age (p=0.045), cN stage (p=0.038), ER status (p=0.004), PR status (p=0.019), HER2 status (p<0.001), Ki-67 percentage (p=0.001), molecular subtyping (p<0.001), axillary intervention (p<0.001), use of adjuvant hormone therapy (p=0.002), grade (p=0.044), distant metastasis (p<0.001), overall survival (OS, p=0.005), and disease-free surviv al (DFS, p=0.003), were significantly different between patients who achieved pCR and nonpCR patients. Menopausal status (p=0.044), HER2 status (p<0.001), Ki-67 status (p=0.001), molecular subtyping (p=0.031), and pertuzumab use (p=0.044) were identified as predictive factors for pCR. Conclusion: Patients who achieved pCR were younger; had higher Ki-67 percentage; had lower ER and PR positivity; had higher HER2 positivity; had grade 3 disease; and had better OS and DFS. Being premenopausal, having HER2 posi tivity, having a Ki-67 percentage greater than 25, being in the HER2-positive molecular subtype, and receiving pertu zumab were favorable predictive factors for pCR. Keywords: Breast cancer, clinical features, d
Corresponding Author: Mukaddes Yılmaz